SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Genaera Corp
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tom pope who wrote (43)5/7/2005 12:56:17 AM
From: DewDiligence_on_SI   of 96
 
And so the stock craters after digesting this news:

These were the first Evizon AMD data from a controlled trial, and the data were mediocre at best. Moreover, the release of the data from the 10mg, 20mg, and 40mg cohorts in bundled form suggests that management is trying to hide the data pertaining to individual doses.

In short, Evizon’s efficacy is now legitimately “in play” for the first time. The probability of technical success of GENR’s AMD project just went down, and the stock price reacted accordingly, IMHO.

[Disclosure: was long from 1H03 to 2H04, when I turned bearish, as detailed in numerous posts on InvestorsHub.]
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News